India’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser use. Drugmakers warn the move could disrupt API production, cause medicine shortages and impact exports, as ammonia is a critical input and alternative sourcing options remain limited.